The RUBIN project "ATHANA" develops innovative therapeutic approaches for the treatment of infectious diseases through nanoparticle-based targeting of active compunds. Leading companies and research institutions from Thuringia, which are active in the pharmaceutical sector or in infection research, have joined forces for this purpose. Infectious diseases caused by fungi represent a special and often underestimated problem. Systemic fungal infections are on the rise and pose a major challenge to modern medicine, as diagnosis is often too late and treatment options are limited. As a proof-of-concept for nanoparticle therapy, ATHANA aims to develop a drug candidate against invasive fungal infections that can be patented.